PURPOSE: In head and neck squamous cell carcinoma (HNSCC) cells, Rap1 shuttles between the nucleus and cytoplasm. Prior findings suggested that Rap1 may modulate the beta-catenin-independent Wnt pathway in some settings, but the role of Rap1 in beta-catenin-dependent Wnt signaling remains undefined. EXPERIMENTAL DESIGN AND RESULTS: We observed that beta-catenin bound to active Rap1 in vitro and Rap1 activated beta-catenin/T-cell factor (TCF)-dependent transcription. Immunofluorescence studies showed that ectopic expression of Rap1 increased nuclear translocation of beta-catenin. Overexpression of active Rap1 facilitated an increase in beta-catenin-mediated transcription that was abrogated by dominant-negative TCF4. Conversely, small interfering RNA-mediated inhibition of endogenous Rap1 expression inhibited beta-catenin/TCF-mediated transcription as well as invasion of HNSCC. Furthermore, inhibition of Rap1 expression downregulated the expression of matrix metalloproteinase 7, a transcriptional target of beta-catenin/TCF. In HNSCC cells stably transfected with beta-catenin or treated with lithium chloride or Wnt3A to stabilize endogenous beta-catenin, inhibition of Rap1 expression led to decreases in the free pool of beta-catenin. Immunohistochemical studies of tissue from HNSCC patients revealed that increased beta-catenin intensity correlated with higher tumor stage. Furthermore, the prognostic effect of active Rap1 on tumor N stage was found to depend on cytosolic beta-catenin expression (P < 0.013). When beta-catenin is high, higher Rap1GTP intensity is associated with more advanced N stage. CONCLUSIONS: The findings suggest that Rap1 enhances beta-catenin stability and nuclear localization. In addition to indicating that Rap1 has a significant role in regulating beta-catenin and beta-catenin-dependent progression to more advanced N-stage lesions, these data highlight Rap1 as a potential therapeutic target in HNSCC.
PURPOSE: In head and neck squamous cell carcinoma (HNSCC) cells, Rap1 shuttles between the nucleus and cytoplasm. Prior findings suggested that Rap1 may modulate the beta-catenin-independent Wnt pathway in some settings, but the role of Rap1 in beta-catenin-dependent Wnt signaling remains undefined. EXPERIMENTAL DESIGN AND RESULTS: We observed that beta-catenin bound to active Rap1 in vitro and Rap1 activated beta-catenin/T-cell factor (TCF)-dependent transcription. Immunofluorescence studies showed that ectopic expression of Rap1 increased nuclear translocation of beta-catenin. Overexpression of active Rap1 facilitated an increase in beta-catenin-mediated transcription that was abrogated by dominant-negative TCF4. Conversely, small interfering RNA-mediated inhibition of endogenous Rap1 expression inhibited beta-catenin/TCF-mediated transcription as well as invasion of HNSCC. Furthermore, inhibition of Rap1 expression downregulated the expression of matrix metalloproteinase 7, a transcriptional target of beta-catenin/TCF. In HNSCC cells stably transfected with beta-catenin or treated with lithium chloride or Wnt3A to stabilize endogenous beta-catenin, inhibition of Rap1 expression led to decreases in the free pool of beta-catenin. Immunohistochemical studies of tissue from HNSCC patients revealed that increased beta-catenin intensity correlated with higher tumor stage. Furthermore, the prognostic effect of active Rap1 on tumor N stage was found to depend on cytosolic beta-catenin expression (P < 0.013). When beta-catenin is high, higher Rap1GTP intensity is associated with more advanced N stage. CONCLUSIONS: The findings suggest that Rap1 enhances beta-catenin stability and nuclear localization. In addition to indicating that Rap1 has a significant role in regulating beta-catenin and beta-catenin-dependent progression to more advanced N-stage lesions, these data highlight Rap1 as a potential therapeutic target in HNSCC.
Authors: Matthew A Ginos; Grier P Page; Bryan S Michalowicz; Ketan J Patel; Sonja E Volker; Stefan E Pambuccian; Frank G Ondrey; George L Adams; Patrick M Gaffney Journal: Cancer Res Date: 2004-01-01 Impact factor: 12.701
Authors: Cathy Cole Lanning; Janelle L Daddona; Rebecca Ruiz-Velasco; Shulamith H Shafer; Carol L Williams Journal: J Biol Chem Date: 2004-08-10 Impact factor: 5.157
Authors: U Impola; V J Uitto; J Hietanen; L Hakkinen; L Zhang; H Larjava; K Isaka; U Saarialho-Kere Journal: J Pathol Date: 2004-01 Impact factor: 7.996
Authors: Leo S Price; Amra Hajdo-Milasinovic; Jun Zhao; Fried J T Zwartkruis; John G Collard; Johannes L Bos Journal: J Biol Chem Date: 2004-05-27 Impact factor: 5.157
Authors: Catherine Hogan; Norberto Serpente; Patricia Cogram; Catherine Rose Hosking; Carl Uli Bialucha; Stephan Michael Feller; Vania M M Braga; Walter Birchmeier; Yasuyuki Fujita Journal: Mol Cell Biol Date: 2004-08 Impact factor: 4.272
Authors: Elizabeth Ntantie; Patrick Gonyo; Ellen L Lorimer; Andrew D Hauser; Nathan Schuld; Donna McAllister; Balaraman Kalyanaraman; Michael B Dwinell; John A Auchampach; Carol L Williams Journal: Sci Signal Date: 2013-05-28 Impact factor: 8.192
Authors: John N Griffin; Florencia Del Viso; Anna R Duncan; Andrew Robson; Woong Hwang; Saurabh Kulkarni; Karen J Liu; Mustafa K Khokha Journal: Dev Cell Date: 2017-12-28 Impact factor: 12.270
Authors: Boban M Erovic; Dae Kim; Clarissa Cassol; David P Goldstein; Jonathan C Irish; Sylvia L Asa; Ozgur Mete Journal: Endocr Pathol Date: 2012-12 Impact factor: 3.943